OssDsign publishes prospectus in connection with a fully guaranteed rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, HONGKONG, NEW ZEELAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE SECTION “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.
The board of directors of OssDsign AB (publ) (”OssDsign” or the ”Company”) has prepared a prospectus in connection with the rights issue of approximately SEK 240 million announced through a press release on 2 March 2021 (the “Rights Issue”). The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority and is available on the Company’s website.
The prospectus regarding the Rights Issue has been approved and registered by the Swedish Financial Supervisory Authority and is now available on the Company’s website (https://www.ossdsign.com/), and on ABG Sundal Collier’s website (www.abgsc.com). The prospectus will also be available on the Swedish Financial Supervisory Authority’s website (www.fi.se).
Company presentations via webcast in connection with the Rights Issue
In connection with the subscription period of the Rights Issue, which runs from 21 April 2021 to 7 May 2021, the Company’s CEO Morten Henneveld will present the Company, the reasons for the rights issue and further information on the Company’s strategy and future plans. The presentations will be held via webcast, hosted by ABG Sundal Collier. For further information on the presentations and how to register, please see below.
Date: 21 April 2021
Time: 17:30 – 18:30 CET
Link to join webcast: https://abgsc.webex.com/abgsc/onstage/g.php?MTID=ecac3600825d2845b68b250d266f0a081
Event number (access code): 183 748 6593
Event password: RNuwNMjc733
Date: 5 May 2021
Time: 12:00 – 13:00 CET
Link to join webcast: https://abgsc.webex.com/abgsc/onstage/g.php?MTID=ee06e75653939aa53b81d9b25429478e8
Event number (access code): 183 803 5632
Event password: rDJtyJvG223
ABG Sundal Collier is the sole global coordinator and bookrunner in connection with the Rights Issue. Setterwalls Advokatbyrå is legal advisor to the Company.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: [email protected]
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: [email protected].
OssDsign’s vision is to provide regenerative solutions to all patients with cranial or spinal bone defects, so they can be restored and healed as naturally as possible. Driven by a commitment to give patients back the lives they deserve, OssDsign collaborate with surgeons to engineer better healing by integrating biomaterials with clinical design. OssDsign is headquartered in Sweden but supplies hospitals globally with implants for use in cranial reconstructions and other orthopaedic surgery applications.
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction where such offer would be considered illegal. This press release does not constitute an offer to sell or an offer to buy or subscribe for shares issued by the Company in any jurisdiction where such offer or invitation would be illegal. In a member state within the European Economic Area ("EEA"), securities referred to in the press release may only be offered in accordance with applicable exemptions under Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”).
This press release is not an offer or invitation to acquire or subscribe for shares or other securities in the United States. The securities that have been mentioned in this release are not allowed to be sold in the United States without registration, or without application of an exception from registration, according to the applicable U.S. Securities Act from 1933 (“Securities Act”), or as a part of a transaction that is not covered by the registration requirements according to the Securities Act. There is no intention to register any shares or securities mentioned herein in the United States or to announce a public offering of such securities in the United States. The information in this press release shall not be published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States of America, Australia, Japan, Canada, Hong Kong, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction in which the release, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would demand additional registration or other actions according to Swedish law. Acts in contrary to this instruction can constitute a crime according to applicable securities laws.
The prospectus that has been prepared in connection with the Rights Issue described in this press release was published by the Company on April 20, 2021. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is available on OssDsign’s website, https://www.ossdsign.com/. The approval of the prospectus by the Swedish Financial Supervisory Authority shall not be regarded as an approval of the shares. This release is however not a prospectus in accordance to the definition in the Prospectus Regulation. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the prospectus. Thus, investors are encouraged to review the prospectus in its entirety. In accordance with article 2 k of the Prospectus Regulation this press release constitutes an advertisement. OssDsign has not authorized any offer to the public of shares or rights in any other member state of the EEA than Sweden. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares. An investment decision to acquire or subscribe for shares in the Rights Issue shall only be made based on publicly available information.
To the extent this press release contains forward-looking statements, such statements does not constitute facts and are characterized by words such as “shall”, “expect”, “believe” “assess”, “intend”, “estimate” and similar expressions. Such statements reflects OssDsign’s intentions, views or present expectations or assumptions. Such forward-looking statements are based on OssDsign’s current plans, estimates and projections, which have been made to the best of OssDsign’s ability. However, OssDsign does not assert that these statements will be correct in the future. Forward-looking statements are associated with risks and uncertainties which are difficult to predict and which generally cannot be affected by OssDsign. It should be contemplated that actual events or outcomes may differ materially from what is included or expressed in such forward-looking statements.
Västra Hamnen: Chordate kommenterar CE-godkännande för migränbehandling (video)
Västra Hamnen Corporate Finance har publicerat en videointervju med Chordate Medicals VD Anders Weilandt. I intervjun diskuteras betydelsen av den överraskande tidiga tilldelningen av CE-godkännande för bolagets utrustning för behandling av kronisk migrän....
VD Anders Karlssons anförande från Idogens årsstämma
Idogen (Nasdaq First Growth Market: IDOGEN) utvecklar tolerogena cellterapier för att undvika att biologiska läkemedel, transplanterade organ eller kroppens egen vävnad angrips av patientens immunförsvar. Bolagets längst framskridna projekt IDO 8 syftar till att återst...
Communique from annual general meeting in Senzime AB (publ)
Annual report and resultsThe annual general meeting adopted the income statement and the balance sheet for the financial year 2020 and resolved, in accordance with the board of directors’ proposal, that the result according to the approved income statement should be transferred to a new account. No...
Kommuniké från årsstämma i Senzime AB (publ)
Årsredovisning och resultatÅrsstämman fastställde resultat- och balansräkningarna och beslutade, i enlighet med styrelsens förslag, att resultatet enligt den fastställda resultaträkningen skulle överföras i ny räkning. Någon utdelning lämnas inte.AnsvarsfrihetÅrsstämman beviljade styrelseledamöterna...